<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003777</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066906</org_study_id>
    <secondary_id>UPCC-6398</secondary_id>
    <secondary_id>ALZA-98-023-ii</secondary_id>
    <secondary_id>NCI-V99-1518</secondary_id>
    <nct_id>NCT00003777</nct_id>
  </id_info>
  <brief_title>Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer</brief_title>
  <official_title>A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Drugs such as amifostine may prevent the side effects of radiation therapy. Combining more&#xD;
      than one drug and combining radiation therapy and surgery with chemotherapy may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining surgery, radiation therapy,&#xD;
      and combination chemotherapy in treating patients who have recurrent head and neck cancer&#xD;
      that has been treated previously with radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the effectiveness and toxic effects of intensive salvage therapy and&#xD;
           radiotherapy in previously irradiated patients with recurrent head and neck cancer.&#xD;
&#xD;
        -  Determine the feasibility and effectiveness of amifostine at limiting or minimizing side&#xD;
           effects of repeat irradiation in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo surgical resection of gross disease (if not already done) followed&#xD;
      by 4-6 weeks of rest. Patients receive radiotherapy over 5 consecutive days on weeks 1, 2, 4,&#xD;
      and 5. Intravenous cisplatin is administered on days 1-3 and 29-31. Intravenous amifostine is&#xD;
      administered 15-30 minutes prior to radiotherapy and cisplatin therapy. Patients receive&#xD;
      fluorouracil IV continuously on days 1-4 and 29-32.&#xD;
&#xD;
      Patients are followed every month for 1 year, every 2 months for 1 year, every 3 months for 1&#xD;
      year, every 4 months for 1 year, then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution&#xD;
  </why_stopped>
  <start_date type="Actual">December 1998</start_date>
  <completion_date type="Actual">April 20, 2001</completion_date>
  <primary_completion_date type="Actual">April 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent or new primary squamous cell carcinoma of the head&#xD;
             and neck occurring in a previously irradiated field&#xD;
&#xD;
          -  Pathologic stage of recurrence must be rT3-4 and/or rN2-3&#xD;
&#xD;
          -  The following sites are eligible:&#xD;
&#xD;
               -  Oral cavity, oropharynx, or hypopharynx: Any rT2-4 and/or clinical rN+&#xD;
&#xD;
               -  Larynx: Any rT4, rT3 with perineural invasion, or any rT with clinical rN+&#xD;
&#xD;
               -  Any site: Positive margin(s), at least 2 nodes or ECS&#xD;
&#xD;
          -  No primary tumor of the nasopharynx&#xD;
&#xD;
          -  Must be eligible for or have undergone complete resection which leaves behind no gross&#xD;
             residual disease&#xD;
&#xD;
          -  Must have prior head and neck irradiation of 45-75 Gy&#xD;
&#xD;
          -  Lifetime spinal cord radiotherapy dose no greater than 50 Gy&#xD;
&#xD;
          -  No ongoing RTOG late morbidity of grade 3 or greater (unless correctable by surgery)&#xD;
&#xD;
          -  No active acute radiation mucositis from previous radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL (transfusion allowed)&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT or SGPT no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction, unstable angina, coronary heart failure, or uncontrolled&#xD;
             arrhythmias within past 6 months&#xD;
&#xD;
          -  No severe cerebrovascular disease or hypotension not caused by antihypertensive&#xD;
             medication&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No allergy to cisplatin, fluorouracil, or amifostine&#xD;
&#xD;
          -  No uncontrolled insulin-dependent diabetes mellitus or other medical condition&#xD;
             interfering with wound healing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for tumor recurrence (except adjuvant chemotherapy)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy treatment records must be available&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior salvage surgery consisting of partial laryngectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Machtay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2003</study_first_posted>
  <last_update_submitted>January 11, 2022</last_update_submitted>
  <last_update_submitted_qc>January 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2022</last_update_posted>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage IV lip and oral cavity cancer</keyword>
  <keyword>recurrent lip and oral cavity cancer</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage IV hypopharyngeal cancer</keyword>
  <keyword>recurrent hypopharyngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage IV laryngeal cancer</keyword>
  <keyword>recurrent laryngeal cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage IV paranasal sinus and nasal cavity cancer</keyword>
  <keyword>recurrent paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage IV oropharyngeal cancer</keyword>
  <keyword>recurrent oropharyngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

